Meet Jill Furman, JD, New Director of FDA’s Office of Compliance

Drug evaluation and research help to ensure drug quality and therefore, public safety. Leading the charge in this critical mission is Jill Furman, J.D., the Director of the Office of Compliance within the Center for Drug Evaluation and Research (CDER).  

Jill Furman began her education at the University of Pennsylvania, where she earned her bachelor's degree. She then attended the Boston University School of Law, earning her law degree.  

After completing her education, Furman embarked on a successful legal career. She started as an Assistant District Attorney at the Suffolk County District Attorney's Office in Boston, Massachusetts, where she prosecuted criminal cases in state appellate and trial courts. Her courtroom experience and understanding of the legal system laid a foundation for her future endeavors. 

Furman's commitment to consumer protection led her to join the U.S. Department of Justice's (DOJ) Consumer Protection Branch. For more than 22 years, she handled a wide range of consumer protection matters, including civil and criminal litigation under the Food, Drug, and Cosmetic Act.  

In 2020, Furman joined the Food and Drug Administration (FDA) as the Deputy Director of the Office of Compliance. 

In her current role as the Director of the Office of Compliance within CDER, Furman leads efforts to protect the public from poor-quality, unsafe, and ineffective drug products. She develops proactive compliance strategies and implements risk-based enforcement actions, ensuring the highest standards of drug safety and efficacy are maintained. 

Furman is shaping compliance, quality, and drug safety issues. As such, AAHP continues to engage as appropriate while monitoring how Furman’s positions may affect the ongoing relationships and shared efforts between FDA and our industry.